Vyome advances VT-1953 program with $7.9 million cash
Vyome Holdings (NASDAQ:HIND) reported second-quarter 2026 results and provided a corporate update, highlighting progress on VT-1953, its lead program for symptoms associated with malignant fungating wounds.










